BMS Korea is in dilemma over price of new leukemia drug

Published: 2008-05-14 06:59:00

Updated: 2008-05-14 06:59:00

BMS Korea is reportedly in internal discussion over the Ministry for Health, Welfare and Family Affair committee's decision on the price of Sprycel, a new drug for the disease.

On May 7, the committee decided to fix 55,000 won per 70-milligram-pill.

"Our official announcement will be made a...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK